Drugs / MTPS9579A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05129423 | Jul 2022 → Jul 2024 | chronic idiopathic urticaria | Genentech, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04092582 | Oct 2019 → May 2022 | asthma | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTPS9579A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04092582 ↗ |
| Action | Inhibit | “necessary to achieve 95% active tryptase inhibition from baseline” PMID 39250147 ↗ Sep 2024 |
| Modality | Monoclonal antibody | “MTPS9579A, an anti-tryptase antibody” PMID 39250147 ↗ Sep 2024 |
| Route | Intravenous | “Phase 2a patients (n = 134) received 1800 mg MTPS9579A or placebo intravenously every 4 weeks for 48 weeks” PMID 39250147 ↗ Sep 2024 |